Day: February 27, 2026

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

Written by Customer Service on February 27, 2026. Posted in Public Companies.

Remibrutinib, a highly selective oral BTKi, has potential to be first targeted therapy approved for CSU in EuropeImprovements with remibrutinib observed as early as Week 1 in REMIX 1 & 2, with favorable safety profile including no liver safety concerns through Week 521CSU affects nearly 4 million people in Europe, with over 50% of patients remaining symptomatic despite H1-antihistamines2-4Basel, February 27, 2026 – Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for remibrutinib. The opinion supports its use as an oral treatment for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1‑antihistamine treatment. “The introduction of remibrutinib represents...

Jura Provides Disclosure Regarding Shareholder Claim by PEL’s CEO

Written by Customer Service on February 27, 2026. Posted in Public Companies.

CALGARY, Alberta, Feb. 27, 2026 (GLOBE NEWSWIRE) — Jura Energy Corporation (TSXV: JEC) (“Jura” or the “Company”) updates its shareholders that it is aware that Mr. Shahzad Zaheer, a minority shareholder of the Company, has filed a Statement of Claim in the Ontario Superior Court of Justice against the Company and its directors (the “Claim”). Jura is aware that Mr. Zaheer is the owner and Chief Executive Officer of Petroleum Exploration (Private) Limited (“PEL”). As previously announced by the Company, PEL has lost a multi-million US dollar international arbitration initiated by Jura’s subsidiaries, Frontier Holdings Limited and Spud Energy Pty Limited (the “Jura Subsidiaries”). Enforcement efforts in respect of that award are ongoing. Mr. Zaheer’s Claim contains a number of allegations, including that the acquisition by IDL Investments...

BrightSpring Health Services, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Written by Customer Service on February 27, 2026. Posted in Earnings Releases And Operating Results.

LOUISVILLE, Ky., Feb. 27, 2026 (GLOBE NEWSWIRE) — BrightSpring Health Services, Inc. (“BrightSpring” or the “Company”) (NASDAQ: BTSG), a leading provider of home and community-based health services for complex populations, today announced financial results for the fourth quarter and full year ended December 31, 2025 and initiated full year 2026 Revenue and Adjusted EBITDA1 guidance. Fourth Quarter 2025 Financial Highlights(note: all figures represent continuing operations and exclude the Community Living business)Net revenue of $3,551 million, up 29.3% compared to $2,747 million in the fourth quarter of 2024 Gross profit of $413 million, up 21.8% compared to $339 million in the fourth quarter of 2024 Net income of $49.6 million compared to net income of $4.3 million in the fourth quarter of 2024 Adjusted EBITDA1 of $184 million,...

Amneal Reports Fourth Quarter and Full Year 2025 Financial Results

Written by Customer Service on February 27, 2026. Posted in Earnings Releases And Operating Results.

‒ Full Year 2025 Performance Met or Exceeded All Guidance Metrics and 2026 Reflects Another Year of Growth – ‒ Q4 2025 Net Revenue of $814 million; GAAP Net Income of $35 million; Diluted Income per Share of $0.11 ‒ ‒ Q4 2025 Adjusted Net Income of $68 million, Adjusted EBITDA of $175 million; Adjusted Diluted EPS of $0.21 ‒ ‒ Full Year 2025 Net Revenue of $3.02 billion; GAAP Net Income of $72 million; Diluted Income per Share of $0.22 ‒ ‒ Full Year 2025 Adjusted Net Income of $269 million; Adjusted EBITDA of $688 million; Adjusted Diluted EPS of $0.83 ‒ ‒ Provides 2026 Financial Guidance of $3.05 to $3.15 billion in net revenue, $720 to $760 million in Adjusted EBITDA, and $0.93 to $1.03 in Adjusted Diluted EPS – BRIDGEWATER, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”)...

Banco Itaú Chile Announces Fourth Quarter 2025 Management Commentary

Written by Customer Service on February 27, 2026. Posted in Public Companies.

SANTIAGO, Chile, Feb. 27, 2026 (GLOBE NEWSWIRE) — BANCO ITAÚ CHILE (SSE: ITAUCL) announced today its Management Commentary for the fourth quarter ended December 31, 2025. For the full report, please refer to the webpage: https://ir.itau.cl/results-and-reports/quarterly-reports/ On Monday, March 2nd, 2026, at 11:00 A.M. Santiago time (9:00 A.M. ET) the Company’s management team will host a conference call to discuss the financial results. The conference call will be hosted by André Gailey, CEO; Emiliano Muratore, CFO; and Andrés Perez, Chief Economist. Webinar Details: Online registration: https://mzgroup.zoom.us/webinar/register/WN_f1Mv_CJ5RJ-YTQrwzMohEA All participants must pre-register using this link to join the webinar. Upon registering, each participant will be provided with details to connect to the call. Q&A session: The...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma

Written by Customer Service on February 27, 2026. Posted in Public Companies.

If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationi The decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesiiPARIS, FRANCE, 27 FEBRUARY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the conditional marketing authorization of Ojemda® (tovorafenib) as monotherapy for the treatment of patients 6 months of age and older with paediatric low-grade glioma (pLGG) harbouring a...

Pro Kapital Council approved Consolidated Interim Report for IV Quarter and 12 Months of 2025 (Unaudited)

Written by Customer Service on February 27, 2026. Posted in Earnings Releases And Operating Results.

MANAGEMENT REPORT Real Estate Development Tallinn During the fourth quarter of 2025 we completed the construction of the white building in our Uus- Kindrali project, located in Kristiine City, Tallinn. Client inspections and the signing of real rights agreements commenced in November, and by year-end, we had successfully closed 39 residential units in the white building. The remaining pre-sold units are scheduled to be closed during the first quarter of 2026. By the end of the reporting period, corresponding with the completion of construction, 78% of the sellable area (m²) had been sold. At the same time, the construction activities continued on a second seven-storey residential building with 90 units, located next to the white building at Sammu Street 10 / Seebi Street 24a, Tallinn. By the year end all the windows had been installed;...

Pro Kapital Council approved Consolidated Interim Report for IV Quarter and 12 Months of 2025 (Unaudited)

Written by Customer Service on February 27, 2026. Posted in Earnings Releases And Operating Results.

Press Release: Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness

Written by Customer Service on February 27, 2026. Posted in Public Companies.

Acoziborole Winthrop, developed by DNDi and Sanofi, receives CHMP positive opinion as three-tablet, single-dose treatment for most common form of sleeping sickness Recommendation based on phase 2/3 study demonstrating up to 96 percent success rates at 18 months across both early and advanced stages of T.b. gambiense, the most common form of sleeping sicknessThe therapy, given as a single dose of three tablets, could offer a simpler alternative to longer, more complex regimens and help support the World Health Organization’s (WHO) goal of eliminating the disease by 2030Sanofi will donate the medicine to WHO through its philanthropic arm Foundation SKinshasa / Paris / Geneva / Amsterdam – February 27, 2026. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion...

CORRECTION: Eesti Energia Group Unaudited Results for 2025

Written by Customer Service on February 27, 2026. Posted in Public Companies.

Correction have been made in the condensed consolidated interim income statement: 2024 PROFIT/(LOSS) BEFORE TAX EUR +38.6 million (before EUR -38.6 million) — Sales Revenues and Profitability In 2025, the Baltic energy sector experienced significant developments and challenges, both of which had a major impact on energy security and prices. The energy market, which was previously stable and predictable, has undergone rapid changes in recent years, with prices becoming increasingly volatile. In 2025 sales revenue totalled EUR 1,646.9 million, an 8% decrease year-on-year. EBITDA declined to EUR 317.2 million, an 20% decrease year-on-year. Reported net loss for the year was EUR 82.6 million (EUR –95.5 million year-on-year). The net loss for 2025 includes asset impairments in the amount of EUR 197.6 million, of which EUR 194.5 million...

Day: February 27, 2026

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals